Home › Research › Treatments
Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center
Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, Dennis BC, Freeman SW et al.. Alzheimer's & dementia (Amsterdam, Netherlands), 2026-07-01
Topic: Risk, prevention and care in population studies
Introduction The anti-amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease. Methods This study highlights 51 patients who received at least one donanemab infusion at our memory center between October 4, 2024 and October 3, 2025. Results Of the 48 patients who underwent at least one surveillance brain MRI after starting donanemab, 10 (20.8%) had ARIA detected. ε4 carriers more frequently displayed amyloid-related imaging abnormalities (ARIA-cortical superficial hemosiderosis/microhemorrhages [ARIA-H] and/or ARIA-edema/effusion) ( p = 0.033) and ARIA-H ( p = 0.020) compared to ε4 non-carriers. No patients developed symptomatic ARIA. Seven (13.7%) patients experienced infusion-related side effects. Eight (15.7%) patients discontinued donanemab due to ARIA progression (5), severe infusion reactions (2), and need for anticoagulants (1). Discussion Donanemab may be safely used in a real-world setting with structured monitoring. ARIA was observed in 20.8% of patients in this implementation cohort. Larger-scale multicenter data are needed to benchmark rates.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shields, L. B. E., Hust, H. S., Cooper, G. E., Kluthe, T., Hart, R. N., Thaliath, A. P., et al. (2026). Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70438
Vancouver
Shields LBE, Hust HS, Cooper GE, Kluthe T, Hart RN, Thaliath AP, et al. Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center. Alzheimer's & dementia (Amsterdam, Netherlands). 2026. doi:10.1002/dad2.70438. PMID: 42614867.
BibTeX
@article{shields2026-42614867,
author = {Shields, L. B. E. and Hust, H. S. and Cooper, G. E. and Kluthe, T. and Hart, R. N. and Thaliath, A. P. and Dennis, B. C. and Freeman, S. W. and others},
title = {{Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2026},
doi = {10.1002/dad2.70438},
pmid = {42614867},
url = {https://doi.org/10.1002/dad2.70438}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of the 48 patients who underwent at least one surveillance brain MRI after starting donanemab, 10 (20.8%) had ARIA detected. ε4 carriers more frequently displayed amyloid-related imaging abnormalities (ARIA-cortical superficial hemosiderosis/microhemorrhages [ARIA-H] and/or ARIA-edema/effusion) ( p = 0.033) and ARIA-H ( p = 0.020) compared to ε4 non-carriers.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants51
- Effect size20.8%; 13.7%; 15.7%
- Evidence strengthModerate
How this study scored 64/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 37 of the 58 points we could judge it on, which is 64 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 51 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42614867) |
| Free to read | 2 / 2 | Free to read |
| Points | 37 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 37 of the 58 points we could judge it on is 64 out of 100. |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “medical-center”
3 studies in the library carry the topic tag “medical-center”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.